Compare ACIW & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACIW | GRFS |
|---|---|---|
| Founded | 1975 | 1940 |
| Country | United States | Spain |
| Employees | 2930 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.0B |
| IPO Year | 1996 | 2008 |
| Metric | ACIW | GRFS |
|---|---|---|
| Price | $49.19 | $7.44 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $62.50 | $10.15 |
| AVG Volume (30 Days) | ★ 648.2K | 358.8K |
| Earning Date | 05-07-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.80% |
| EPS Growth | ★ 13.09 | N/A |
| EPS | ★ 0.69 | N/A |
| Revenue | ★ $1,009,780,000.00 | N/A |
| Revenue This Year | $9.67 | $4.49 |
| Revenue Next Year | $7.41 | $6.42 |
| P/E Ratio | $71.87 | ★ $18.67 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $38.05 | $6.96 |
| 52 Week High | $61.08 | $10.23 |
| Indicator | ACIW | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 39.33 |
| Support Level | $38.92 | $7.26 |
| Resistance Level | $54.10 | $8.41 |
| Average True Range (ATR) | 1.26 | 0.11 |
| MACD | -0.21 | -0.04 |
| Stochastic Oscillator | 12.92 | 13.87 |
ACI Worldwide Inc develops, markets, and installs a portfolio of software products focused on facilitating electronic payments. The firm's products are sold and supported directly and through distribution networks covering three geographic regions - the Americas, EMEA, and Asia Pacific. ACI software products process payment transactions for retail banking clients, billers such as utilities and healthcare providers, and community banks and credit unions. ACI's customers are financial institutions all over the world, but the majority of the revenue is generated in the United States and EMEA regions. The company's operating segment includes Payment Software and Biller. The company generates the majority of its revenue from the Payment Software segment.
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.